跳至主要内容
临床试验/NCT02336360
NCT02336360已完成1 期

A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451

Avid Radiopharmaceuticals1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
6
试验地点
1
主要终点
Urine Analysis - Total Integrated Radioactivity Excreted in Urine

研究概览

简要总结

This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Subjects who passed screening in an Avid-sponsored study in which flortaucipir will be administered

排除标准

  • Subjects who have withdrawn informed consent
  • Investigator or sponsor believes it is in the best interest of the subject to be removed from the trials

研究组 & 干预措施

Urine Analysis

Experimental

Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.

干预措施: Flortaucipir F18 (Drug)

结局指标

主要结局

Urine Analysis - Total Integrated Radioactivity Excreted in Urine

时间窗: 0-360 minutes post injection

Total integrated radioactivity excreted in urine over time will be determined to augment previous radiation dosimetry calculations.

次要结局

未报告次要终点

研究者

发起方
Avid Radiopharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Augmenting Flortaucipir Dosimetry Estimates | 临床试验